Poster & Motion Graphic Design 2025 Software: Adobe After Effects/Illustrator Client: School ProjectThis project explores a major issue in the American healthcare system: cancer drug prices continue to rise while the actual survival benefits for patients remain largely unchanged.
Using a petri dish as a visual metaphor, the design takes the form of a radial chart. Each ring represents the years 2000–2020, while cost increases around the chart from $0 to over $250,000. Each drug is mapped by its approval year, price, and survival benefit, highlighting the growing gap between cost and effectiveness. A supporting timeline features the case of Gleevec, whose price increased by over 400% without improving outcomes, alongside data that shows the financial burden placed on patients.
The project extends into motion, turning the data into a short video that guides viewers through the issue. Together, the work uses data visualization and storytelling to raise awareness and encourage conversations around rising drug costs and patient impact.
Part 1: Diagnosis: Metastatic Pricing (Original Poster Design)
From the start, I knew I wanted somehow incorporate “cells” somewhere in my poster. My idea was for the cells to be the main representation of my data. I sketched a variety of ways I could accomplish this and ended up with a stacked spiral with dots for my cell design.
Initially, my graph followed a bar graph, but throughout my process I changed it to be more fitting to my topic and overall unique. This lead me to think directly more to science, cells, and labs, and I landed at a petri dish with cells. Since I knew my graph would be circular, I made it so that the data would function and work the radial graph design. After this, I added details such as a grain gradient effect to my illustration to add depth.
Poster Design Part 2: Price of Survival (Motion Graphic Video) Voiceover Script
: Created By ElevenLabs
"For decades, we've fought cancer with groundbreaking new drugs, bringing new hope to patients and families. But behind this hope, a hidden crisis is growing: the price of these breakthroughs is skyrocketing, and it's a cost that simply doesn't add up.
Let's look at the evidence. Over the past 20 years, the price of new cancer drugs has exploded, far outpacing inflation and average wages. What was once a significant medical expense is now a staggering financial burden.All too often, these soaring costs are not matched by a proportional increase in how long patients live. The immense financial burden on families and our healthcare system is simply not justified by a significant improvement in overall survival. In short, the value is broken.
This is more than just a healthcare issue; it's about building a smarter, more fair system. So, where do we go from here? We have the power to advocate for a new approach. This means championing transparency, supporting reform, and empowering everyone to ask: 'Is this cost worth the survival benefit?
By working together, we can ensure that the goal of a longer life doesn't come at the price of a lifetime of debt."